Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 6/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | CASP6 | P55212 | 1/20 | 0.33 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28426483 | 0.94 | SMN1; SMN2 (0.38) | EPHX2KMT2AL3MBTL1MEN1ALDH1A1 | |
| SCHEMBL28432841 | 0.93 | TSHR (0.40) | EPHX2KMT2AMEN1ALDH1A1SMN1; SMN2 | |
| SCHEMBL5115508 | 0.90 | LMNA (0.40) | EPHX2LMNAALDH1A1CHRM1SMN1; SMN2 | |
| SCHEMBL3516005 | 0.86 | EPHX2 (0.34) | EPHX2LMNAMCOLN3HCRTR1HCRTR2 | |
| SCHEMBL17203730 | 0.84 | CA2 (0.37) | EPHX2KMT2ALMNAL3MBTL1MEN1 | |
| SCHEMBL9101570 | 0.80 | LMNA (0.38) | KMT2ALMNAL3MBTL1GAAMEN1 | |
| SCHEMBL30667146 | 0.80 | LMNA (0.38) | KMT2ALMNAL3MBTL1GAAMEN1 | |
| SCHEMBL531432 | 0.80 | LMNA (0.47) | KMT2ALMNAL3MBTL1GAAMEN1 | |
| SCHEMBL30666645 | 0.80 | LMNA (0.38) | KMT2ALMNAL3MBTL1GAAMEN1 | |
| SCHEMBL30716899 | 0.80 | LMNA (0.38) | KMT2ALMNAL3MBTL1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107098886-B | Prazinone-containing quinazolinone PARP-1/2 inhibitor and preparation method, pharmaceutical composition and application thereof | 中国医学科学院药物研究所 | 2020-07-14 | — | — | CN | disclosed |
| EP-2906539-B1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | HIVIH (FR) | 2017-06-21 | — | — | EP | disclosed |
| US-9475802-B2 | Inhibitors of viral replication, their process of preparation and their therapeutical uses | LABORATOIRE BIODIM (FR) | 2016-10-25 | — | — | US | disclosed |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | LABORATOIRE BIODIM (FR) | 2015-10-01 | — | — | US | disclosed |
| EP-2906539-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2015-08-19 | — | — | EP | disclosed |
| WO-2014057103-A1 | INHIBITORS OF VIRAL REPLICATION, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES | LABORATOIRE BIODIM (FR) | 2014-04-17 | — | — | WO | disclosed |
| US-20140024583-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-23 | — | — | US | disclosed |
| US-8501746-B2 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2013-08-06 | — | — | US | disclosed |
| US-8318949-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20120014906-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-19 | — | — | US | disclosed |
| US-8049016-B2 | Thiazole derivatives which inhibit stearoyl-CoA desaturase enzymes | NOVARTIS AG (CH) | 2011-11-01 | — | — | US | disclosed |
| WO-2007143597-A9 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-11 | — | — | WO | disclosed |
| EP-2029572-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-11-03 | — | — | EP | disclosed |
| US-20090264444-A1 | Organic compounds | XENON PHARMACEUTICALS INC. (CA) | 2009-10-22 | — | — | US | disclosed |
| US-20090156615-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-06-18 | — | — | US | disclosed |
| EP-2029572-A2 | ORGANIC COMPOUNDS | Novartis AG (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007143597-A2 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2007-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156615-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | EPHX2 905/4885KMT2A 2098/4885LMNA 2176/4885 |
| US-20120014906-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | EPHX2 905/4885KMT2A 2098/4885LMNA 2176/4885 |
| US-20150274718-A1 | Inhibitors of Viral Replication, Their Process of Preparation and Their Therapeutical Uses | RPL35, EIF2AK2, MAVS | EPHX2 4069/4885KMT2A 3036/4885LMNA 1718/4885 |
| US-20090264444-A1 | Organic compounds | SCD, SCD5, FADS2 | EPHX2 905/4885KMT2A 2098/4885LMNA 2176/4885 |
| US-20140024583-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | EPHX2 905/4885KMT2A 2098/4885LMNA 2176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.